Globus Medical stock holds at Neutral as BTIG cites revenue miss
BTIG reiterated a Neutral rating on Globus Medical (GMED) after its Q3 2026 revenue of $763.7M missed expectations, down 0.7% YoY. Adjusted EPS beat at $1.23. The company lowered its full-year revenue guidance to $3.09B. BMO downgraded GMED to Market Perform with a $78 price target.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance downgrade are likely to drive the stock lower in the short term.
Market read
Primary earnings and guidance update for GMED, affecting its valuation and investor sentiment.
What to watch
Strong growth in Enabling Technology and a solid adjusted EPS beat may offset the revenue shortfall.
Background
Globus Medical reported Q3 2026 earnings with a slight revenue decline and a cut to its full-year revenue outlook.
Ticker impact
Q3 2026 results missed revenue expectations and lowered full-year revenue guidance.
downward pressure as market prices in weaker revenue and lower guidance
Both the earnings miss and the downward revision of full-year revenue are new, material facts that typically trigger sell pressure.
Market effects
Medical device sector may see broader scrutiny on revenue forecasts.
U.S. healthcare stocks could experience slight pullback.
Limited to investors focused on U.S. med‑tech equities.
Counterpoint
The stock may be oversold; the revenue miss is modest and adjusted earnings beat could support a rebound.
Key entities
- CompanyGlobus Medical
Medical device manufacturer (ticker GMED).
- AnalystBTIG
Reiterated a Neutral rating on GMED.
